SPRB
Spruce
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 1
Sell signal 2
Downward Gap
Revenue Beats Expectation
EPS Below Expectations
Key Stats
--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
About SPRB
Spruce Biosciences, Inc.
A late-stage biopharmaceutical company that developing novel therapies for rare endocrine disorders
Pharmaceutical
Invalid Date
10/09/2020
NASDAQ Stock Exchange
21
12-31
Common stock
611 Gateway Boulevard, Suite 740, South San Francisco, California 94080
--
Spruce Biosciences, Inc., was originally incorporated as a limited liability company in Delaware in November 2014. The company is a late-stage biopharmaceutical company focused on developing and commercializing new therapies for rare endocrine diseases with unmet medical needs. The company is initially developing a wholly-owned product candidate, tildacerfont, as a potential first non-steroidal therapy to provide significantly improved disease control and reduced steroid burden for patients with typical congenital adrenal hyperplasia.
Company Financials
EPS
SPRB has released its 2024 Q3 earnings. EPS was reported at -0.21, versus the expected -0.24, beating expectations. The chart below visualizes how SPRB has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
SPRB has released its 2024 Q4 earnings report, with revenue of 697.00K, reflecting a YoY change of -75.86%, and net profit of -23.56M, showing a YoY change of -136.77%. The Sankey diagram below clearly presents SPRB’s revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
